Choosing the Right European Cannabis Market: A Framework for Market Selection

The question companies bring to Europe is usually "how do we enter Germany?" The better question is "which European market should we enter first, and on what evidence?" Those are different questions with different answers, and the second one determines whether the first is worth asking.

Largest is not the same as best. The largest market in a category is normally the one with the most competitors, the highest cost of entry, the most established distribution and the least tolerance for an unknown brand. First entry should be chosen to produce a defensible commercial position and usable evidence for the next market - not to maximise theoretical market size on a slide.

Why the biggest market is usually the wrong first market

Three effects work against entering the largest market first. Distribution is already allocated, so the incoming brand pays for access rather than negotiating from strength. Price points have already been set by incumbents with scale advantages. And the cost of failure is highest exactly where the company has least local knowledge.

A smaller market that can be entered quickly, served profitably and learned from is frequently worth more than a position at the bottom of a large one. It produces the reference customers, compliance track record, pricing data and distributor relationships that make the large market entry cheaper twelve months later.

The eleven criteria that decide market order

These criteria are deliberately narrow and answerable. Each should be resolved with evidence about your specific product, not about the cannabis market in general.

• Regulatory accessibility - can this product lawfully be placed on the market, by what route, and in what timeframe?
• Product-market fit - does the format, potency and price point match what this market's buyers actually purchase?
• Competitive intensity - how many credible competitors hold the specific shelf or formulary position you want?
• Distribution access - is the channel open, concentrated, or closed to new entrants without local presence?
• Consumer or clinical demand - is demand observable today, or dependent on a future framework?
• Pricing environment - what does the channel price at, and what remains after every intermediary?
• Market maturity - early markets reward position; mature markets reward efficiency and scale.
• Operational complexity - licences, testing, labelling, local representation, storage and logistics.
• Capital requirement - total cash to first revenue, not just landed cost of the first shipment.
• Speed to market - months to lawful first sale under realistic, not best-case, assumptions.
• Strategic fit - does winning here make the next two markets easier or harder?

Regulatory accessibility is a filter, not a score

Treat regulatory accessibility as a gate applied before anything else is measured. If the product cannot lawfully be sold, the market scores zero regardless of its size, and the only meaningful question becomes whether the route to authorisation is worth funding as a separate project.

Regimes differ sharply within Europe. Medical cannabis frameworks are national and vary in prescribing, import and pharmacy rules. Consumable cannabinoid products in the EU face the novel food authorisation question before lawful placing on the market. Non-EU European markets, including Switzerland and the United Kingdom, operate their own regimes entirely and must be assessed separately rather than assumed to follow EU practice.

Scoring markets so the comparison holds up

Use a weighted score, with weights set by the company's own constraints, and force a decision rather than a description. A capital-constrained brand should weight speed to market, distribution access and capital requirement most heavily. A manufacturer with EU production and long runway should weight regulatory fit, pricing environment and strategic fit.

Score each criterion 1-5 on evidence you can cite. Where a criterion cannot be scored, record it as an open question with an owner and a cost to resolve. A comparison with three honest gaps is more useful than one with eleven confident guesses.

Two disciplines make the output reliable: score at least three markets, and re-score after the first commercial conversations in each. Distributor feedback routinely changes the pricing and access scores by more than any desk research does.

Sequencing: first market, second market, and the case for a beachhead

Choose the first market for learnability and defensibility, the second for scale. A beachhead market should satisfy three conditions: lawful access within the funding horizon, at least one credible distribution route the company can win, and transferable evidence - compliance documentation, clinical or retail references, and pricing proof that shortens the next entry.

Sequencing also protects the balance sheet. Running two entries in parallel with one team typically produces two under-resourced launches rather than a hedge.

Common errors in market selection

The recurring mistakes are consistent across companies and categories:

• Choosing a market because of population size rather than reachable demand.
• Choosing a market because an inbound partner made contact first.
• Treating the EU as a single market and assuming one approval travels.
• Assuming home-market pricing survives European distribution margins.
• Confirming demand but never confirming banking, payments and logistics for the category.
• Committing to exclusivity before a single unit has been sold.

What to evaluate next

Take three to five candidate markets, apply the eleven criteria with your own weighting, and identify the two open questions per market that would change the ranking if answered. That short list of questions is the actual research brief - and it is usually far cheaper to resolve than companies expect.

Our European cannabis markets overview sets out the country-level picture we work from. For a structured first pass on your own position, the cannabis market entry calculator scores your product and capital against European market conditions, and our cannabis consulting services cover the selection and entry work end to end.